VERVE THERAPEUTICS INC (VERV) Stock Earnings & Estimates
USA - NASDAQ:VERV - US92539P1012 - Common Stock
11.13 USD
+0.03 (+0.27%)
11.2 USD
+0.07 (+0.63%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.94M | 11.758M 506.08% | 32.332M 174.98% | 47.068M 45.58% | 20.556M -56.33% | 17.748M -13.66% | 21.42M 20.69% | 25.364M 18.41% | 90.61M 257.24% | 265.71M 193.25% | 544.17M 104.80% | |
| EBITDA YoY % growth | -162.89M -90.45% | -217.669M -33.63% | -221.907M -1.95% | -272.449M -22.78% | -342.242M -25.62% | -377.782M -10.38% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -165.69M -90.30% | -223.124M -34.66% | -228.66M -2.48% | -254.313M -11.22% | -299.307M -17.69% | -345.988M -15.60% | -367.914M -6.34% | -430.202M -16.93% | -394.706M 8.25% | -155.04M 60.72% | 79.56M 151.32% | |
| Operating Margin | -8,540.72% | -1,897.64% | -707.23% | -540.31% | -1,456.06% | -1,949.45% | -1,717.62% | -1,696.11% | -435.61% | -58.35% | 14.62% | |
| EPS YoY % growth | -2.92 38.44% | -3.12 -6.85% | -2.35 24.68% | -2.54 -8.20% | -3.00 -18.11% | -2.77 7.79% | -2.99 -7.80% | -3.23 -8.08% | -3.00 6.95% | -1.74 41.90% | 1.00 157.31% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.72 -21.59% | -0.74 -25.63% | -0.74 -27.50% | -0.71 -104.00% |
| Revenue Q2Q % growth | 4.777M -28.62% | 4.376M -36.26% | 4.306M -67.08% | 8.211M -75.10% |
| EBITDA Q2Q % growth | -72.42M -30.39% | -74.46M -43.59% | -75.48M -53.06% | N/A |
| EBIT Q2Q % growth | -69.611M -18.31% | -72.426M -27.26% | -72.841M -29.92% | -71.359M -94.78% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.35 40.68% | -0.67 | 0.32 | 47.66% |
| Q4 2024 Q2Q % growth | -0.58 15.94% | -0.71 | 0.13 | 18.30% |
| Q3 2024 Q2Q % growth | -0.59 18.06% | -0.71 | 0.12 | 17.01% |
| Q2 2024 Q2Q % growth | -0.59 32.18% | -0.70 | 0.11 | 15.43% |
| Q1 2024 Q2Q % growth | -0.59 29.76% | -0.73 | 0.14 | 18.87% |
| Q4 2023 Q2Q % growth | -0.69 -2.99% | -0.84 | 0.15 | 17.70% |
| Q3 2023 Q2Q % growth | -0.72 8.86% | -0.94 | 0.22 | 23.11% |
| Q2 2023 Q2Q % growth | -0.87 -3.57% | -0.94 | 0.07 | 7.09% |
| Q1 2023 Q2Q % growth | -0.84 -35.48% | -0.79 | -0.05 | -5.72% |
| Q4 2022 Q2Q % growth | -0.67 -3.08% | -0.78 | 0.11 | 14.10% |
| Q3 2022 Q2Q % growth | -0.79 -68.09% | -0.75 | -0.04 | -5.27% |
| Q2 2022 Q2Q % growth | -0.84 87.39% | -0.66 | -0.18 | -27.26% |
| Q1 2022 Q2Q % growth | -0.62 | -0.67 | 0.05 | 7.50% |
| Q4 2021 Q2Q % growth | -0.65 | -0.56 | -0.09 | -15.56% |
| Q3 2021 Q2Q % growth | -0.47 | -0.46 | -0.01 | -1.83% |
| Q2 2021 Q2Q % growth | -6.66 | -0.50 | -6.16 | -1,232.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 32.976M 479.03% | 9.563M | 23.413M | 244.83% |
| Q4 2024 Q2Q % growth | 13.08M 154.33% | 4.042M | 9.038M | 223.60% |
| Q3 2024 Q2Q % growth | 6.865M 120.24% | 2.866M | 3.999M | 139.53% |
| Q2 2024 Q2Q % growth | 6.692M 219.73% | 2.448M | 4.244M | 173.37% |
| Q1 2024 Q2Q % growth | 5.695M 305.63% | 2.066M | 3.629M | 175.65% |
| Q4 2023 Q2Q % growth | 5.143M 409.21% | 1.192M | 3.951M | 331.46% |
| Q3 2023 Q2Q % growth | 3.117M 235.16% | 982.943K | 2.134M | 217.11% |
| Q2 2023 Q2Q % growth | 2.093M | 771.885K | 1.321M | 171.15% |
| Q1 2023 Q2Q % growth | 1.404M | 524.576K | 879.424K | 167.64% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.12% | -2.43% | -1.93% | 8.61% |
| Revenue | 3.49% | -2.15% | 13.96% | 91.06% |